Clinical Features and Risk Factors Associated With Worse Outcome in Patients Hospitalized for Covid-19 Pneumonia
Clinical Features and Risk Factors Associated With Worse Outcome in Patients Hospitalized for Covid-19 Pneumonia in France
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Yves HANSMANN, MD, PhD
- Phone Number: 33 3 69 55 09 78
- Email: yves.hansmann@chru-strasbourg.fr
Study Locations
-
-
-
Strasbourg, France, 67091
- Recruiting
- Service des Maladies Infectieuses et Tropicales
-
Sub-Investigator:
- Yvon Ruch, MD
-
Sub-Investigator:
- Coralie LE HYARIC, MD
-
Sub-Investigator:
- François Danion, MD
-
Contact:
- Yves HANSMANN, MD, PhD
- Phone Number: 33 3 69 55 09 78
- Email: yves.hansmann@chru-strasbourg.fr
-
Contact:
- Charlotte KAEUFFER, MD
- Phone Number: 33 3 69 55 11 87
- Email: Charlotte.kaeuffer@chru-strasbourg.fr
-
Principal Investigator:
- Yves HANSMANN, MD, PhD
-
Sub-Investigator:
- Antonin HUGEROT, MD
-
Sub-Investigator:
- Olivier HINSCHBERGER, MD
-
Sub-Investigator:
- Joy MOOTIEN, MD
-
Sub-Investigator:
- Martin MARTINOT, MD, PhD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Major patient (≥18 years of age)
- Admitted in March 2020 for confirmed Covid-19 lung disease (nasopharyngeal smear or sputum with SARS-CoV-2 positive PCR).
Exclusion Criteria:
- Patient who has expressed opposition to participation in the study.
- Mild forms of infection that do not require hospitalization,
- Subject under safeguard of justice
- Subject under guardianship or trusteeship
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Identification of risk factors for severity (death or transfer to resuscitation) of Covid-19 infection
Time Frame: Files analysed retrospectively from March 1st, 2020 to April 15, 2020 will be examined]
|
Files analysed retrospectively from March 1st, 2020 to April 15, 2020 will be examined]
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 7773 (UH Montpellier)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.